FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

REGISTER

now for free

Nick Thatcher

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Register to see full profile

Co-author Network

Register to see all co-authors

Publications

TOP 3
Fred R Hirsch; Pasi A Janne; Edward S Kim; Tetsuya Mitsudomi; Myung-Ju Ahn; Federico Cappuzzo; Hak Choy; Wilfried E Eberhardt; David R Gandara; Luis Paz-Ares; Robert Pirker; Frances A Shepherd; Nick Thatcher; Yi-Long Wu; Tony Shu Kam Mok
Epidermal growth factor receptor inhibition in lung cancer: status 2012.
Fiona H Blackhall; Richard Booton; Nick Thatcher; Keith Kerr
The impact on the multidisciplinary team of molecular profiling for personalized therapy in non-small cell lung cancer.
Paul Lorigan; Raffaele Califano; Corinne Faivre-Finn; Anthony Howell; Nick Thatcher
Lung cancer after treatment for breast cancer.

Register to see all publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Register to see more

Geonetwork of Nick Thatcher (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Register to see more

All Publications

2013: Fred R Hirsch; Pasi A Janne; Edward S Kim; Tetsuya Mitsudomi; Myung-Ju Ahn; Federico Cappuzzo; Hak Choy; Wilfried E Eberhardt; David R Gandara; Luis Paz-Ares; Robert Pirker; Frances A Shepherd; Nick Thatcher; Yi-Long Wu; Tony Shu Kam Mok
Epidermal growth factor receptor inhibition in lung cancer: status 2012.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2013;8(3):373-84.
2013: Fiona H Blackhall; Richard Booton; Nick Thatcher; Keith Kerr
The impact on the multidisciplinary team of molecular profiling for personalized therapy in non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2013;79(2):101-3.
2010: Paul Lorigan; Raffaele Califano; Corinne Faivre-Finn; Anthony Howell; Nick Thatcher
Lung cancer after treatment for breast cancer.
The lancet oncology 2010;11(12):1184-92.
2010: Fiona H Blackhall; Mary O'brien; Peter Schmid; Marianne Nicolson; Paul Taylor; Tsveta Milenkova; Sarah J Kennedy; Nick Thatcher
A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(8):1285-8.
2009: Eitan Amir; Laszlo Mandoky; Fiona H Blackhall; Nick Thatcher; Walter Klepetko; Hendrik Jan Ankersmit; Mir Ali Reza Hoda; Gyula Ostoros; Magdolna Dank; Balazs Dome
Antivascular agents for non-small-cell lung cancer: current status and future directions.
Expert opinion on investigational drugs 2009;18(11):1667-86.
2009: Mark A Socinski; Egbert F Smit; Paul Lorigan; Kartik Konduri; Martin Reck; Aleksandra Szczesna; Johnetta Blakely; Piotr Serwatowski; Nina A Karaseva; tudor ciuleanu; Jacek Jassem; Mircea Dediu; Shengyan Hong; Carla Visseren-Grul; Axel-Rainer Hanauske; Coleman K Obasaju; Susan C Guba; Nick Thatcher
Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4787-92.
2009: N A Bayman; H Sheikh; B Kularatne; P Lorigan; F Blackhall; Nick Thatcher; Corinne Faivre-Finn
Radiotherapy for small-cell lung cancer-Where are we heading?
Lung cancer (Amsterdam, Netherlands) 2009;63(3):307-14.
2008: Ethan Amir; Sarah Hughes; Fiona Blackhall; Nick Thatcher; Gyula Ostoros; Jozsef Timar; Jozsef Tovari; Gabor Kovacs; Balazs Dome
Targeting blood vessels for the treatment of non-small cell lung cancer.
Current cancer drug targets 2008;8(5):392-403.
2008: Neil A Bayman; Fiona Blackhall; Pooja Jain; Lip Lee; Nick Thatcher; Corinne Faivre-Finn
Management of unresectable stage III non-small-cell lung cancer with combined-modality therapy: a review of the current literature and recommendations for treatment.
Clinical lung cancer 2008;9(2):92-101.
2008: Fred R Hirsch; Rafal Dziadziuszko; Nick Thatcher; Helen Mann; Claire Watkins; Dinah V Parums; Georgina Speake; Brian Holloway; Paul A Bunn; Wilbur A Franklin
Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer.
Cancer 2008;112(5):1114-21.
2008: Paul A Bunn; Nick Thatcher
Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion.
The oncologist 2008;13 Suppl 1():37-46.
2008: Paul A Bunn; Nick Thatcher
Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.
The oncologist 2008;13 Suppl 1():1-4.
2007: Richard Booton; Tim Ward; Linda Ashcroft; Julie Morris; Jim Heighway; Nick Thatcher
ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(10):902-6.
2007: Nick Thatcher
The place of targeted therapy in the patient management of non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2007;57 Suppl 2():S18-23.
2007: Roberta Ferraldeschi; Nick Thatcher; Paul Lorigan
Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial.
Expert review of anticancer therapy 2007;7(5):635-40.
2007: Roberta Ferraldeschi; Sofia Baka; Babita Jyoti; Corinne Faivre-Finn; Nick Thatcher; Paul Lorigan
Modern management of small-cell lung cancer.
Drugs 2007;67(15):2135-52.
2006: Fred R Hirsch; Marileila Varella-Garcia; Paul A Bunn; Wilbur A Franklin; Rafal Dziadziuszko; Nick Thatcher; ALEX CHANG; Purvish Parikh; Jose R Pereira; tudor ciuleanu; Joachim von Pawel; Claire Watkins; Angela Flannery; Gillian Ellison; Emma Donald; Lucy Knight; Dinah Parums; Nick Botwood; Brian Holloway
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(31):5034-42.
2006: SC White; Paul Lorigan; Geoffrey P Margison; Jennifer M Margison; F Martin; Nick Thatcher; Heather Anderson; Malcolm Ranson
Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer.
British journal of cancer 2006;95(7):822-8.
2006: ALEX CHANG; Purvish Parikh; Sumitra Thongprasert; Eng Huat Tan; Reury-Perng Perng; Domingo Ganzon; Chih-Hsin Yang; Chao-Jung Tsao; Claire Watkins; Nick Botwood; Nick Thatcher
Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006;1(8):847-55.
2006: Richard Booton; Richard Booten; Tim Ward; Jim Heighway; Linda Ashcroft; Julie Morris; Nick Thatcher
Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006;1(7):679-83.
2006: Sofia Baka; C Manegold; E Buchholz; K Schott-von-Römer; Paul Lorigan; S Nagel; Fiona H Blackhall; L Aschroft; Nick Thatcher
Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2006;53(2):165-70.
2006: Richard Booton; Paul Lorigan; Heather Anderson; Sofia Baka; Linda Ashcroft; M Nicolson; M O'Brien; D Dunlop; K O'Byrne; V Laurence; M Snee; G Dark; Nick Thatcher
A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(7):1111-9.
2006: Fiona H Blackhall; Malcolm Ranson; Nick Thatcher
Where next for gefitinib in patients with lung cancer?
The lancet oncology 2006;7(6):499-507.
2006: Richard Booton; Tim Ward; Jim Heighway; Pat Taylor; Fiona Power; Linda Ashcroft; Julie Morris; Nick Thatcher
Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer.
Cancer 2006;106(11):2421-7.
2006: J E King; Nick Thatcher; C A C Pickering; Philip S Hasleton
Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data.
Histopathology 2006;48(3):223-32.
2005: Corinne Faivre-Finn; L W Lee; Paul Lorigan; C West; Nick Thatcher
Thoracic radiotherapy for limited-stage small-cell lung cancer: controversies and future developments.
Clinical oncology (Royal College of Radiologists (Great Britain)) 2005;17(8):591-8.
2005: Nick Thatcher; ALEX CHANG; Purvish Parikh; José Rodrigues Pereira; tudor ciuleanu; Joachim von Pawel; Sumitra Thongprasert; Eng Huat Tan; Kristine Pemberton; Venice Archer; Kevin Carroll
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).
Lancet 2005;366(9496):1527-37.
2005: Paul Lorigan; John Radford; Anthony Howell; Nick Thatcher
Lung cancer after treatment for Hodgkin's lymphoma: a systematic review.
The lancet oncology 2005;6(10):773-9.
2005: Corinne Faivre-Finn; Paul Lorigan; Catharine West; Nick Thatcher
Thoracic radiation therapy for limited-stage small-cell lung cancer: unanswered questions.
Clinical lung cancer 2005;7(1):23-9.
2005: Sofia Baka; Malcolm Ranson; Paul Lorigan; Sarah Danson; K Linton; I Hoogendam; K Mettinger; Nick Thatcher
A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer.
European journal of cancer (Oxford, England : 1990) 2005;41(11):1547-50.
2005: Nick Thatcher; Corinne Faivre-Finn; Fiona H Blackhall; Heather Anderson; Paul Lorigan
Sequential platinum-based chemotherapy-thoracic radiotherapy in early stage non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(13 Pt 2):5051s-5056s.
2005: Fiona H Blackhall; Pavlos I Papakotoulas; Sarah Danson; Nick Thatcher
Perspectives on novel therapies for bronchial carcinoma.
Expert opinion on pharmacotherapy 2005;6(7):1157-67.
2005: Fiona H Blackhall; Shazza Rehman; Nick Thatcher
Erlotinib in non-small cell lung cancer: a review.
Expert opinion on pharmacotherapy 2005;6(6):995-1002.
2005: Paul Lorigan; Penella J Woll; M E R O'Brien; Linda Ashcroft; Mark R Sampson; Nick Thatcher
Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer.
Journal of the National Cancer Institute 2005;97(9):666-74.
2005: Sofia Baka; Linda Ashcroft; Heather Anderson; M Lind; Paul A Burt; Ronald Stout; I Dowd; D Smith; Paul Lorigan; Nick Thatcher
Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(10):2136-44.

2005: Fiona H Blackhall; Jaishree Bhosle; Nick Thatcher
Chemotherapy for advanced non-small cell lung cancer patients with performance status 2.
Current opinion in oncology 2005;17(2):135-9.
2005: Michelle N Harvie; Anthony Howell; Nick Thatcher; A Baildam; I Campbell
Energy balance in patients with advanced NSCLC, metastatic melanoma and metastatic breast cancer receiving chemotherapy--a longitudinal study.
British journal of cancer 2005;92(4):673-80.
2005: Nick Thatcher; Corinne Faivre-Finn; Paul Lorigan
Management of small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16 Suppl 2():ii235-9.
2004: Sofia Baka; Paul Lorigan; Nick Thatcher
Palliative treatment.
Hematology/oncology clinics of North America 2004;18(2):417-32.
2003: Richard Booton; M Jones; Nick Thatcher
Lung cancer 7: management of lung cancer in elderly patients.
Thorax 2003;58(8):711-20.
2003: Sarah Danson; Mark R Middleton; Kenneth J O'Byrne; Mark Clemons; Malcolm Ranson; Jurjees Hassan; Heather Anderson; Paul A Burt; Corrine Fairve-Finn; Ronald Stout; Isabel Dowd; Linda Ashcroft; Cheryl Beresford; Nick Thatcher
Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma.
Cancer 2003;98(3):542-53.
2003: Sarah Danson; Paul Lorigan; A Arance; Andrew R Clamp; Malcolm Ranson; J Hodgetts; L Lomax; Linda Ashcroft; Nick Thatcher; Mark R Middleton
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2551-7.
2002: Nick Thatcher
The role of chemotherapy (CT) and supportive care (SC) in advanced non-small cell lung cancer (NSCLC).
Lung cancer (Amsterdam, Netherlands) 2002;38 Suppl 3():S71-3.
2002: Jacobus A Burgers; A Arance; Linda Ashcroft; J Hodgetts; L Lomax; Nick Thatcher
Identical chemotherapy schedules given on and off trial protocol in small cell lung cancer: response and survival results.
British journal of cancer 2002;87(5):562-6.
2002: Mark R Middleton; Nick Thatcher; T Brian H McMurry; R Stanley McElhinney; Dorothy J Donnelly; Geoffrey P Margison
Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model.
International journal of cancer. Journal international du cancer 2002;100(5):615-7.
2002: Nick Thatcher
New drugs in small cell lung cancer.
I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.] 2002;1(4):S26-7.
2002: M J Paul; Y Summers; A Hilary Calvert; Gordon J S Rustin; MH Brampton; Nick Thatcher; Mark R Middleton
Effect of temozolomide on central nervous system relapse in patients with advanced melanoma.
Melanoma research 2002;12(2):175-8.
2002: Richard Booton; Nick Thatcher
Chemotherapy in advanced nonsmall cell lung cancer: indication, intensity, and duration.
Current opinion in oncology 2002;14(2):191-8.
2001: SC White; Paul Lorigan; Mark R Middleton; Heather Anderson; J Valle; Y Summers; Paul A Burt; A Arance; Ronald Stout; Nick Thatcher
Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma.
Cancer 2001;92(3):601-8.
2001: Penella J Woll; Nick Thatcher; L Lomax; J Hodgetts; S M Lee; Paul A Burt; Ronald Stout; T Simms; R Davies; R Pettengell
Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: a randomized phase II trial in small-cell lung cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(3):712-9.
2000: Mark R Middleton; SM Lee; A Arance; M Wood; Nick Thatcher; Geoffrey P Margison
O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study.
International journal of cancer. Journal international du cancer 2000;88(3):469-73.
2000: Heather Anderson; Penelope Hopwood; Richard J Stephens; Nick Thatcher; B Cottier; M Nicholson; Robert Milroy; Timothy S Maughan; SJ Falk; M G Bond; Paul A Burt; C Kevin Connolly; M B McIllmurray; J Carmichael
Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer.
British journal of cancer 2000;83(4):447-53.
2000: SC White; SL Cheeseman; Nick Thatcher; Heather Anderson; B Carrington; S Hearn; G Ross; Malcolm Ranson
Phase II study of oral topotecan in advanced non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(3):868-73.
2000: Mark R Middleton; Paul Lorigan; J Owen; Linda Ashcroft; SM Lee; P Harper; Nick Thatcher
A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.
British journal of cancer 2000;82(6):1158-62.
2000: SC White; Heather Anderson; Gordon C Jayson; Linda Ashcroft; Malcolm Ranson; Nick Thatcher
Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(2):201-6.
2000: Mark R Middleton; J Kelly; Nick Thatcher; Dorothy J Donnelly; R Stanley McElhinney; T Brian H McMurry; J E McCormick; Geoffrey P Margison
O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts.
International journal of cancer. Journal international du cancer 2000;85(2):248-52.
2000: MR Ranson; S White; Nick Thatcher
Management of elderly patients with lung cancer.
Current oncology reports 2000;2(1):90-5.
2000: Mark R Middleton; J Kelly; S Goodger; Nick Thatcher; Geoffrey P Margison
Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts.
Cancer chemotherapy and pharmacology 2000;45(1):15-20.
2000: Mark R Middleton; J J Grob; N Aaronson; G Fierlbeck; W Tilgen; S Seiter; M Gore; S Aamdal; Jonathan Cebon; A Coates; B Dreno; M Henz; D Schadendorf; A Kapp; J Weiss; U Fraass; Paul Statkevich; M Muller; Nick Thatcher
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(1):158-66.
1999: Nick Thatcher; E S De Campos; D R Bell; W P Steward; G Varghese; R Morant; J F Vansteenkiste; R Rosso; S B Ewers; E Sundal; E Schatzmann; H Stocker
Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer.
British journal of cancer 1999;80(3-4):396-402.
1998: Mark R Middleton; J M Lunn; C Morris; Gordon J S Rustin; SR Wedge; MH Brampton; Michael Lind; SM Lee; David R Newell; NM Bleehen; Edward S Newlands; A Hilary Calvert; Geoffrey P Margison; Nick Thatcher
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma.
British journal of cancer 1998;78(9):1199-202.
1998: Gordon C Jayson; Mark R Middleton; SM Lee; Linda Ashcroft; Nick Thatcher
A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer.
British journal of cancer 1998;78(3):366-9.
1998: Nick Thatcher
Management of chemotherapy-induced anemia in solid tumors.
Seminars in oncology 1998;25(3 Suppl 7):23-6.
1998: Nick Thatcher; S M Lee; Penella J Woll; Mark R Middleton; Heather Anderson; Paul A Burt; Ronald Stout
Dose intensity in small cell lung cancer.
Seminars in oncology 1998;25(2 Suppl 4):12-8; discussion 45-8.
1997: MR Ranson; G Jayson; S Perkins; H Anderson; Nick Thatcher
Single-agent paclitaxel in advanced non-small cell lung cancer: single-center phase II study using a 3-hour administration schedule.
Seminars in oncology 1997;24(4 Suppl 12):S12-6-S12-9.
1997: Nick Thatcher; G Jayson; B Bradley; M Ranson; Heather Anderson
Gemcitabine: symptomatic benefit in advanced non-small cell lung cancer.
Seminars in oncology 1997;24(3 Suppl 8):S8-6-S8-12.
1997: Penella J Woll; R Basser; T Le Chevalier; P Drings; G Perez Manga; Antoine Adenis; L Seymour; F Smith; Nick Thatcher
Phase II trial of raltitrexed ('Tomudex') in advanced small-cell lung cancer.
British journal of cancer 1997;76(2):264-5.
1997: Nick Thatcher; P Hopwood; H Anderson
Improving quality of life in patients with non-small cell lung cancer: research experience with gemcitabine.
European journal of cancer (Oxford, England : 1990) 1997;33 Suppl 1():S8-13.
1996: Heather Anderson; Nick Thatcher; J Walling; H Hansen
A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer.
British journal of cancer 1996;74(3):460-2.
1996: SM Lee; H Reid; R H Elder; Nick Thatcher; Geoffrey P Margison
Inter- and intracellular heterogeneity of O6-alkylguanine-DNA alkyltransferase expression in human brain tumors: possible significance in nitrosourea therapy.
Carcinogenesis 1996;17(4):637-41.
1995: Nick Thatcher; Heather Anderson; D C Betticher; Malcolm Ranson
Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms.
Anti-cancer drugs 1995;6 Suppl 6():39-48.
1995: D C Betticher; Heather Anderson; Malcolm Ranson; K Meely; Wolfgang Oster; Nick Thatcher
Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study.
British journal of cancer 1995;72(6):1551-5.
1995: Malcolm Ranson; Nick Thatcher
The importance of dose and schedule in chemotherapy for small cell lung cancer.
Anti-cancer drugs 1995;6 Suppl 5():53-63.
1995: D C Betticher; SM Lee; C Morris; M Clemons; Nick Thatcher
Dacarbazine and interferon-alpha 2a in advanced malignant melanoma: high response rate and prolongation of response duration occur in different patient subpopulations.
Melanoma research 1995;5(4):277-82.
1995: E de Campos; J Radford; W Steward; R Milroy; M Dougal; R Swindell; N Testa; Nick Thatcher
Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(7):1623-31.
1995: SM Lee; D C Betticher; Nick Thatcher
Melanoma: chemotherapy.
British medical bulletin 1995;51(3):609-30.
1995: N M Bleehen; Edward S Newlands; SM Lee; Nick Thatcher; P Selby; A Hilary Calvert; Gordon J S Rustin; MH Brampton; M F Stevens
Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(4):910-3.
1995: Penella J Woll; J Hodgetts; L Lomax; F Bildet; V Cour-Chabernaud; Nick Thatcher
Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(3):652-9.
1995: A E Brewster; P Hopwood; Ronald Stout; P A Burt; Nick Thatcher
Single fraction prophylactic cranial irradiation for small cell carcinoma of the lung.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1995;34(2):132-6.
1995: Nick Thatcher; Malcolm Ranson; S M Lee; R Niven; Heather Anderson
Chemotherapy in non-small cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6 Suppl 1():83-94; discussion 94-5.
1995: R Pettengell; Penella J Woll; Nick Thatcher; TM Dexter; Nydia G Testa
Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(1):148-56.
1994: SM Lee; Peter J O'Connor; Nick Thatcher; Derek Crowther; Geoffrey P Margison; D P Cooper
Relationships between the formation of O6-methyldeoxyguanosine by 1-p-carboxyl-3,3-dimethylphenyltriazene in DNA and O6-alkylguanine-DNA alkyltransferase in human peripheral leukocytes.
Cancer research 1994;54(15):4072-6.
1994: Nick Thatcher; P Lorrigan; P Burt; Ronald Stout
Intensive combined-modality therapy in small cell lung cancer.
Seminars in oncology 1994;21(3 Suppl 6):9-22.
1994: SM Lee; Geoffrey P Margison; Nick Thatcher; Peter J O'Connor; Donald P Cooper
Formation and loss of O6-methyldeoxyguanosine in human leucocyte DNA following sequential DTIC and fotemustine chemotherapy.
British journal of cancer 1994;69(5):853-7.
1994: SM Lee; Nick Thatcher; Derek Crowther; Geoffrey P Margison
Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide.
British journal of cancer 1994;69(3):452-6.
1994: E S de Campos; L P Menasce; J Radford; M Harris; Nick Thatcher
Metastatic carcinoma of uncertain primary site: a retrospective review of 57 patients treated with vincristine, doxorubicin, cyclophosphamide (VAC) or VAC alternating with cisplatin and etoposide (VAC/PE).
Cancer 1994;73(2):470-5.
1994: J Prendiville; P Lorigan; F Hicks; B Leahy; Ronald Stout; P Burt; Nick Thatcher
Therapy for small cell lung cancer using carboplatin, ifosfamide, etoposide (without dose reduction), mid-cycle vincristine with thoracic and cranial irradiation.
European journal of cancer (Oxford, England : 1990) 1994;30A(14):2085-90.
1994: Ann Cull; Anna Gregor; P Hopwood; F Macbeth; H Karnicka-Mlodkowska; Nick Thatcher; P Burt; Ronald Stout; K Stepniewska; M Stewart
Neurological and cognitive impairment in long-term survivors of small cell lung cancer.
European journal of cancer (Oxford, England : 1990) 1994;30A(8):1067-74.
1993: M E Van Hoef; John A Radford; A Jones; I E Smith; Helena Earl; Penella J Woll; Nick Thatcher
Urinary-derived monocyte-colony stimulating factor (P-100) following treatment with carboplatin and etoposide in small cell lung cancer (SCLC).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(10):877-81.
1993: J Prendiville; Derek Crowther; Nick Thatcher; Penella J Woll; B W Fox; Alan T McGown; N Testa; P Stern; R McDermott; M Potter
A phase I study of intravenous bryostatin 1 in patients with advanced cancer.
British journal of cancer 1993;68(2):418-24.
1993: John A Hadfield; Alan T McGown; M J Dawson; Nick Thatcher; B W Fox
The suitability of carboplatin solutions for 14-day continuous infusion by ambulatory pump: an HPLC-dynamic FAB study.
Journal of pharmaceutical and biomedical analysis 1993;11(8):723-7.
1993: SM Lee; Geoffrey P Margison; A A Woodcock; Nick Thatcher
Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma.
British journal of cancer 1993;67(6):1356-60.
1993: Heather Anderson; P Hopwood; J Prendiville; John A Radford; Nick Thatcher; L Ashcroft
A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer.
British journal of cancer 1993;67(6):1385-90.
1993: Howard Gurney; D Dodwell; Nick Thatcher; M H Tattersall
Escalating drug delivery in cancer chemotherapy: a review of concepts and practice--Part 2.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(2):103-15.
1993: Howard Gurney; D Dodwell; Nick Thatcher; M H Tattersall
Escalating drug delivery in cancer chemotherapy: a review of concepts and practice--Part 1.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(1):23-34.
1993: J Prendiville; Nick Thatcher; M Lind; R McIntosh; A Ghosh; Peter L Stern; Derek Crowther
Recombinant human interleukin-4 (rhu IL-4) administered by the intravenous and subcutaneous routes in patients with advanced cancer--a phase I toxicity study and pharmacokinetic analysis.
European journal of cancer (Oxford, England : 1990) 1993;29A(12):1700-7.
1993: A von Rohr; A K Ghosh; Nick Thatcher; Peter L Stern
Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy.
British journal of cancer 1993;67(1):163-71.
1992: SM Lee; Joseph Rafferty; R H Elder; C Y Fan; M Bromley; M Harris; Nick Thatcher; Philip Potter; H J Altermatt; T Perinat-Frey
Immunohistological examination of the inter- and intracellular distribution of O6-alkylguanine DNA-alkyltransferase in human liver and melanoma.
British journal of cancer 1992;66(2):355-60.
1992: Nick Thatcher; M Lind; E De Campos; T Cerny
Novel approaches with ifosfamide in small cell lung cancer.
Seminars in oncology 1992;19(1 Suppl 1):68-77.
1992: M Hrubisko; A T Mc Gown; J A Prendiville; J A Radford; Nick Thatcher; B W Fox
Suitability of cisplatin solutions for 14-day continuous infusion by ambulatory pump.
Cancer chemotherapy and pharmacology 1992;29(3):252-5.
1992: SM Lee; Nick Thatcher; Derek Crowther; Geoffrey P Margison
In vivo depletion of O6-alkylguanine-DNA-alkyltransferase in lymphocytes and melanoma of patients treated with CB 10-277, a new DTIC analogue.
Cancer chemotherapy and pharmacology 1992;31(3):240-6.
1992: John A Radford; W D J Ryder; D Dodwell; Heather Anderson; Nick Thatcher
Predicting septic complications of chemotherapy: an analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis.
European journal of cancer (Oxford, England : 1990) 1992;29A(1):81-6.
1992: Howard Gurney; Heather Anderson; J Radford; M R Potter; R Swindell; W Steward; A Kamthan; J Chang; J Weiner; Nick Thatcher
Infection risk in patients with small cell lung cancer receiving intensive chemotherapy and recombinant human granulocyte-macrophage colony-stimulating factor.
European journal of cancer (Oxford, England : 1990) 1992;28(1):105-12.
1991: J Prendiville; J Radford; Nick Thatcher; W Steward; Malcolm Ranson; P Burt; Ronald Stout
Intensive therapy for small-cell lung cancer using carboplatin alternating with cisplatin, ifosfamide, etoposide, mid-cycle vincristine, and radiotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(8):1446-52.
1991: heidi dazzi; P S Hasleton; Nick Thatcher; S Wilkes; D Barnes; W J Gullick
Comparison of epidermal growth factor receptor expression in lung cancer by immunohistochemical staining of both frozen and formalin fixed specimens.
Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology 1991;3(2):69-75.
1991: S M Lee; Nick Thatcher; G P Margison
O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine.
Cancer research 1991;51(2):619-23.
1991: A D Burden; BA Oppenheim; Derek Crowther; Anthony Howell; Godfrey R Morgenstern; John Howard Scarffe; Nick Thatcher
Viridans streptococcal bacteraemia in patients with haematological and solid malignancies.
European journal of cancer (Oxford, England : 1990) 1991;27(4):409-11.
1991: John A Radford; J M Margison; Ric Swindell; Michael Lind; Peter M Wilkinson; Nick Thatcher
The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump.
Journal of cancer research and clinical oncology 1991;117 Suppl 4():S154-6.
1991: Heather Anderson; J Prendiville; Nick Thatcher; John A Radford; Ric Swindell
A randomised study of intravenous bolus versus continuous infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancer.
Journal of cancer research and clinical oncology 1991;117 Suppl 4():S139-40.
1991: A von Rohr; Heather Anderson; R McIntosh; Nick Thatcher
Phase II study with mitomycin, ifosfamide and carboplatin in inoperable non-small cell lung cancer.
European journal of cancer (Oxford, England : 1990) 1991;27(9):1106-8.
1991: Heather Anderson; Howard Gurney; Nick Thatcher; Ric Swindell; John Howard Scarffe; J Weiner
Recombinant human GM-CSF in small cell lung cancer: a phase I/II study.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1991;121():155-61.
1991: Michael Lind; S Gomm; A P Simmonds; L Ashcroft; A Kamthan; Howard Gurney; Nick Thatcher
A phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancer.
Cancer chemotherapy and pharmacology 1991;28(2):142-4.
1991: Howard Gurney; E S de Campos; D Dodwell; A Kamthan; Nick Thatcher
Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer.
European journal of cancer (Oxford, England : 1990) 1991;27(5):565-8.
1990: heidi dazzi; Nick Thatcher; P S Hasleton; A K Chatterjee; R A Lawson
DNA analysis by flow cytometry in malignant pleural mesothelioma: relationship to histology and survival.
The Journal of pathology 1990;162(1):51-5.
1990: Michael Lind; J M Margison; T Cerny; Nick Thatcher; Peter M Wilkinson
The effect of age on the pharmacokinetics of ifosfamide.
British journal of clinical pharmacology 1990;30(1):140-3.
1990: heidi dazzi; P S Hasleton; Nick Thatcher; S Wilkes; Ric Swindell; A K Chatterjee
Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody.
British journal of cancer 1990;61(6):924-6.
1990: D J Dodwell; H Gurney; Nick Thatcher
Dose intensity in cancer chemotherapy.
British journal of cancer 1990;61(6):789-94.
1990: heidi dazzi; Nick Thatcher; P S Hasleton; Ric Swindell
DNA analysis by flow cytometry in nonsmall cell lung cancer: relationship to epidermal growth factor receptor, histology, tumour stage and survival.
Respiratory medicine 1990;84(3):217-23.
1990: Nick Thatcher; heidi dazzi; M Mellor; A Ghosh; B Carrington; R J Johnson; E M Loriaux; R P Craig
Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: a phase II study.
British journal of cancer 1990;61(4):618-21.
1990: Nick Thatcher; M Lind
Carboplatin in small cell lung cancer.
Seminars in oncology 1990;17(1 Suppl 2):40-8.
1990: John A Radford; J M Margison; Ric Swindell; Michael Lind; Peter M Wilkinson; Nick Thatcher
The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump.
Cancer chemotherapy and pharmacology 1990;26(2):144-6.
1990: Michael Lind; H L Roberts; Nick Thatcher; Jeffrey Idle
The effect of route of administration and fractionation of dose on the metabolism of ifosfamide.
Cancer chemotherapy and pharmacology 1990;26(2):105-11.
1990: A G Kamthan; Michael Lind; Nick Thatcher; W P Steward; M H Bronchud; Malcolm Ranson; Ronald Stout
Ifosfamide, doxorubicin and etoposide in small cell lung cancer patients with poor prognosis.
European journal of cancer (Oxford, England : 1990) 1990;26(6):691-4.
1990: Derek Crowther; John Howard Scarffe; Anthony Howell; Nick Thatcher; M Bronchud; W P Steward; N Testa; M Dexter
Growth factor-assisted chemotherapy--the Manchester experience.
Ciba Foundation symposium 1990;148():201-10; discussion 211-4.
1989: Nick Thatcher; heidi dazzi; R J Johnson; S Russell; A K Ghosh; M Moore; G Chadwick; R D Craig
Recombinant interleukin-2 (rIL-2) given intrasplenically and intravenously for advanced malignant melanoma. A phase I and II study.
British journal of cancer 1989;60(5):770-4.
1989: T Cerny; M Lind; Nick Thatcher; Ric Swindell; Ronald Stout
A simple outpatient treatment with oral ifosfamide and oral etoposide for patients with small cell lung cancer (SCLC).
British journal of cancer 1989;60(2):258-61.
1989: Nick Thatcher; M Lind; Ronald Stout; C Payne; K B Carroll; C Campbell; H Moussalli
Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for 'limited' stage small cell carcinoma of the bronchus.
British journal of cancer 1989;60(1):98-101.
1989: M J Lind; Alan T McGown; John A Hadfield; Nick Thatcher; Derek Crowther; B W Fox
The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo.
Biochemical pharmacology 1989;38(11):1835-40.
1989: heidi dazzi; P S Hasleton; Nick Thatcher; D M Barnes; S Wilkes; Ric Swindell; R A Lawson
Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survival.
British journal of cancer 1989;59(5):746-9.
1989: Michael Lind; J M Margison; T Cerny; Nick Thatcher; Peter M Wilkinson
Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma.
Cancer research 1989;49(3):753-7.
1989: W P Steward; John Howard Scarffe; R Austin; E Bonnem; Nick Thatcher; Godfrey R Morgenstern; Derek Crowther
Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions--a phase I dose-toxicity study.
British journal of cancer 1989;59(1):142-5.
1989: Michael Lind; J M Margison; T Cerny; Nick Thatcher; Peter M Wilkinson
Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution.
Cancer chemotherapy and pharmacology 1989;25(2):139-42.
1988: M Bronchud; John Howard Scarffe; Nick Thatcher; Derek Crowther; L M Souza; N K Alton; Nydia G Testa; TM Dexter
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer.
Behring Institute Mitteilungen 1988;(83):327-9.
1988: M H Bronchud; M R Potter; G Morgenstern; M J Blasco; John Howard Scarffe; Nick Thatcher; Derek Crowther; L M Souza; N K Alton; Nydia G Testa
In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients.
British journal of cancer 1988;58(1):64-9.
1988: D B Smith; C Ewen; J Mackintosh; B W Fox; Nick Thatcher; John Howard Scarffe; R Vezin; Derek Crowther
A phase I and pharmacokinetic study of amphethinile.
British journal of cancer 1988;57(6):623-7.
1988: Nick Thatcher; D B Smith; Michael Lind; Heather Anderson; J Barclay; M P Chopra; M D Fitzgerald
Double alkylating agent therapy with ifosfamide and cyclophosphamide for advanced non-small cell lung cancer. From the Manchester Lung Tumour Group.
Cancer 1988;61(1):14-8.
1988: H Anderson; P Hasleton; A B Michie; R J Johnson; Nick Thatcher
24-hour cyclophosphamide infusion therapy for malignant mesothelioma of the pleura.
British journal of diseases of the chest 1988;82(1):64-9.
1987: M H Bronchud; John Howard Scarffe; Nick Thatcher; Derek Crowther; L M Souza; N K Alton; Nydia G Testa; TM Dexter
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer.
British journal of cancer 1987;56(6):809-13.
1987: Nick Thatcher; T Cerny; Ronald Stout; Heather Anderson; P V Barber; R J Wolstenholme; P Barnes; A Deiraniya
Ifosfamide, etoposide, and thoracic irradiation therapy in 163 patients with unresectable small cell lung cancer.
Cancer 1987;60(10):2382-7.
1987: D Smith; John Wagstaff; Nick Thatcher; H Scarffe
A phase I study of rDNA alpha-2b interferon as a 6-week continuous intravenous infusion.
Cancer chemotherapy and pharmacology 1987;20(4):327-31.
1986: T Cerny; D M Barnes; P Hasleton; P V Barber; K Healy; W Gullick; Nick Thatcher
Expression of epidermal growth factor receptor (EGF-R) in human lung tumours.
British journal of cancer 1986;54(2):265-9.
1986: J M Margison; Peter M Wilkinson; T Cerny; Nick Thatcher
A simple quantitative HPLC assay for ifosfamide in biological fluids.
Biomedical chromatography : BMC 1986;1(3):101-3.
1986: T Cerny; J M Margison; Nick Thatcher; Peter M Wilkinson
Bioavailability of ifosfamide in patients with bronchial carcinoma.
Cancer chemotherapy and pharmacology 1986;18(3):261-4.
1985: Nick Thatcher; Ronald Stout; D B Smith; G Grötte; M Winson; H Bassett; K B Carroll
Three months treatment with chemotherapy and radiotherapy for small cell lung cancer.
British journal of cancer 1985;52(3):327-32.
1983: K B Carroll; H Moussalli; D Brown; Nick Thatcher
A comparison between a single agent short course chemotherapy regimen and a quadruple prolonged course regimen for small-cell bronchogenic carcinoma of limited extent.
British journal of diseases of the chest 1983;77(2):171-8.

Register to see more

Copyright © 2011 Elsevier Inc. All rights reserved.